Table 4.
Multivariate linear regression of AU/ml (Architect) or U/ml (Elecsys) adjusted by age, sex, and BMI (kg/m2).
| Architect (Abbott) |
Elecsys (Roche) |
||||||
|---|---|---|---|---|---|---|---|
| Beta (95 %CI) | Standardized beta | P value | Beta (95 %CI) | Standardized beta | P value | ||
| S0 | Age (in years, continuous) | −0.04(-0.65; 0.57) | −0.01 | 0.90 | 0.001(-0.004; 0.005) | 0.02 | 0.76 |
| Sex (female vs male) | 12.30(-1.87; 26.47) | 0.09 | 0.09 | 0.03(-0.07; 0.13) | 0.03 | 0.57 | |
| BMI (kg/m2, continuous) | 3.75(1.67; 5.84) | 0.19 | < 0.01 | −0.001(-0.02; 0.01) | −0.01 | 0.90 | |
| S1 | Age (in years) | −11.05(-19.29; −2.81) | −0.14 | 0.01 | −0.89(-1.69; −0.10) | −0.11 | 0.03 |
| Sex (female vs male) | 101.33(-90.79; 293.45) | 0.05 | 0.30 | −14.73(–33.33; 3.86) | −0.08 | 0.12 | |
| BMI (kg/m2, continuous) | 32.69(4.44; 60.94) | 0.12 | 0.02 | 2.47(-0.26; 5.21) | 0.10 | 0.08 | |
| S2 | Age (in years, continuous) | −109.98(-174.20; −45.76) | −0.18 | < 0.01 | −18.60(-28.28; −8.92) | −0.20 | < 0.01 |
| Sex (female vs male) | 295.93(-1201.10; 1792.95) | 0.02 | 0.70 | −51.95(-277.58; 173.68) | −0.02 | 0.65 | |
| BMI (kg/m2) | 16.92(-203.20; 237.05) | 0.01 | 0.88 | 7.08(-26.10; 40.25) | 0.02 | 0.68 | |
| S3 | Age (in years, continuous) | –23.05(-31.73; −14.37) | −0.27 | < 0.01 | −19.69(-25.88; −13.50) | −0.31 | < 0.01 |
| Sex (female vs male) | −15.60(-217.87; 186.66) | −0.01 | 0.88 | −7.56(-151.90; 136.79) | < 0.01 | 0.92 | |
| BMI (kg/m2, continuous) | 0.37(-29.37; 30.11) | < 0.01 | 0.98 | 10.72(-10.51; 31.94) | 0.05 | 0.32 | |
BMI, Body mass index （kg/m2); CI, confidence interval.
Architect: Architect SARS-CoV-2 IgG II Quant (Abbott Laboratories); Elecsys: Elecsys anti-SARS-CoV-2 S (Roche Diagnostics).
S0: Within 1 week before the first vaccination, S1: within 1 week before the second vaccination, S2: 4–5 weeks after the second vaccination, S3: 6 months after the second vaccination.